



CXC Chemokine Responses of Respiratory Epithelial Cells to *Streptococcus pneumoniae*



Rikki Marie Ann Graham, BSc (Hons)

A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy
from the University of Adelaide

September 2005

Discipline of Microbiology and Immunology
School of Molecular and Biomedical Sciences
The University of Adelaide
Adelaide, S.A., Australia

Abstract	vii
Declaration	x
Acknowledgements	xi
List of Abbreviations	xiii

Chapter One: General Introduction

1.1 Historical background	1
1.2 The pneumococcal surface	3
1.2.1 Phase variation	4
1.3 <i>Streptococcus pneumoniae</i> as a pathogen	4
1.3.1 Nasopharyngeal colonisation and progression to disease	5
1.4 Pneumococcal vaccines	6
1.4.1 Polysaccharide vaccines	6
1.4.2 Polysaccharide-protein conjugated vaccines	7
1.4.3 Common protein vaccines	9
1.5 Antimicrobial resistance	9
1.6 Pneumococcal virulence factors	10
1.6.1 Choline-binding protein A (CbpA)	11
1.6.1.1 CbpA as an adhesin	13
1.6.1.2 Binding of Factor H	15
1.6.1.3 Chemokine release in response to CbpA	16
1.6.2 Pneumococcal surface protein A (PspA)	16
1.6.3 Pneumolysin (Ply)	19
1.6.3.1 Ply in pathogenesis	19
1.6.3.2 Effects of Ply at a cellular level	21
1.6.3.3 Ply and cytokine release	22
1.6.3.4 Ply structure and function	23
1.7 Pathology of pneumococcal disease	26
1.7.1 Histology	26

1.7.2 Roles of cytokines in inflammation	27
1.8 Chemokines	28
1.8.1 CXC Chemokines	29
1.8.2 Bacterial induction of CXC chemokines	30
1.9 Aims of the work in this thesis	30

Chapter Two: Materials and Methods	32
---	-----------

2.1 Chemicals and reagents	32
2.1.1 Antibiotics	32
2.2 Bacterial growth media	32
2.3 Eukaryotic cell line growth and maintenance	33
2.4 Trypan Blue exclusion assay for cell viability	34
2.5 Bacterial strains and cloning vectors	34
2.6 Oligodeoxynucleotides	36
2.7 Protein purification	38
2.7.1 Expression of recombinant proteins	38
2.7.2 Purification of CbpA and PspA by Ni-NTA Chromatography	38
2.7.3 Purification of Ply by column chromatography	39
2.8 Protein analysis	40
2.8.1 SDS-PAGE	40
2.8.2 Preparation of whole cell lysates (WCL)	40
2.8.3 Western blot analysis	40
2.8.4 Haemolysis assay	41
2.8.5 LPS removal from protein preparations with Polymyxin-B	41
2.9 DNA isolation and manipulation	42
2.9.1 Agarose gel electrophoresis	42
2.9.2 Pneumococcal chromosomal DNA isolation	42
2.9.3 Plasmid miniprep	43
2.9.4 Restriction endonuclease digestion of DNA	43

2.9.5 DNA ligation	43
2.9.6 Polymerase chain reaction (PCR)	44
2.9.7 Purification of PCR product	44
2.9.8 Cloning of PCR product	45
2.9.9 DNA sequencing and analysis	45
2.10 RNA isolation and manipulation	46
2.10.1 RNA extraction from eukaryotic cells	46
2.10.2 Reverse-transcription PCR (RT-PCR)	46
2.10.3 Real-time reverse-transcription PCR	47
2.11 Transformation of <i>E. coli</i>	48
2.11.1 Preparation of competent cells	48
2.11.2 Transformation of <i>E. coli</i>	48
2.12 Transformation of <i>S. pneumoniae</i>	48
2.12.1 Preparation of competent cells	48
2.12.2 Transformation of pneumococci	49
2.12.3 Back-	49
2.13 IL-8 Enzyme-linked immunosorbent assay (ELISA)	50
2.14 Infection of epithelial cell monolayers with <i>S. pneumoniae</i> D39	51

Chapter Three: Characterisation of Respiratory Epithelial Cell CXC Chemokine Responses to *Streptococcus pneumoniae* 52

3.1 Introduction	52
3.2 Results	54
3.2.1 Determination of optimal dose of <i>S. pneumoniae</i> infection	54
3.2.2 Determination of optimal timepoints of infection	56
3.2.3 CXC chemokine response of A549 cells to <i>S. pneumoniae</i> infection	56
3.2.4 Secretion of IL-8 by type II pneumocytes in response to infection with <i>S. pneumoniae</i> .	57

3.2.5 CXC chemokine response of Detroit-562 cells to infection with <i>S. pneumoniae</i> D39	57
3.2.6 Secretion of IL-8 protein by nasopharyngeal cells in response to infection with <i>S. pneumoniae</i> D39	58
3.3 Discussion	58

Chapter Four: Role of Pneumococcal Proteins in Respiratory Epithelial Cell CXC Chemokine Responses

4.1 Introduction	61
4.2 Mutant studies	62
4.2.1 Chemokine mRNA response of Type II pneumocytes to <i>S. pneumoniae</i> D39 CbpA ⁻ and PspA ⁻ insertion-duplication mutants	63
4.2.2 Chemokine mRNA response of nasopharyngeal (Detroit-562) cells to <i>S. pneumoniae</i> D39, CbpA ⁻ and PspA ⁻	64
4.2.3 Release of IL-8 by respiratory epithelial cells in response to WT D39, CbpA ⁻ and PspA ⁻	64
4.2.4 Production of deletion mutants	65
4.2.4.1 Construction of in-frame deletion mutants	66
4.2.5 Chemokine response of A549 and Detroit-562 cells to infection with D39, ΔCbpA, ΔPspA, and ΔPly	69
4.2.5.1 IL-8 release by respiratory epithelial cells in response to <i>S. pneumoniae</i> deletion mutants	70
4.3 Protein studies	72
4.3.1 Chemokine responses to pneumococcal proteins purified from recombinant <i>E. coli</i>	72
4.3.2 Expression of pneumococcal proteins in <i>E. coli</i> BL21(DE3) <i>lpxM</i> ⁻	74
4.3.3 IL-8 and MIP-2α mRNA response of respiratory epithelial cells to CbpA and PspA	75

4.3.4 Secretion of IL-8 by respiratory epithelial cells in response to CbpA and PspA	76
4.3.5 Chemokine induction by type II pneumocytes and nasopharyngeal cells in response to Ply	77
4.4 Discussion	78
4.4.1 CbpA suppresses IL-8 and MIP-2 α production from both A549 and Detroit-562 cells	78
4.4.2 PspA stimulates IL-8 and MIP-2 α production from A549 cells but not Detroit-562 cells	83
4.4.3 The role of Ply in the CXC chemokine response of respiratory epithelial cells	86

Chapter Five: Investigation of the Specific Domains Responsible for CXC Chemokine Inhibition by CbpA	88
---	-----------

5.1 Introduction	88
5.2 Results	89
5.2.1 Investigation of regions of CbpA responsible for inhibition of the chemokine response from A549 and Detroit-562 cells	89
5.2.2 Construction of <i>cbpA</i> domain deletion mutants	90
5.2.3 Chemokine mRNA response of respiratory epithelial cells to CbpA domain mutants	90
5.2.4 IL-8 production by respiratory epithelial cells in response to CbpA domain mutants	92
5.3 Discussion	93

Chapter Six: Investigation of the Specific Domains Responsible for CXC Chemokine Induction by PspA	96
---	-----------

6.1 Introduction	96
6.2 Results	97

6.2.1 The role of specific PspA domains in eliciting a chemokine response from respiratory epithelial cells	97
6.2.2 Production of PspA domain deletion mutants	97
6.2.3 Chemokine response of respiratory epithelial cells to PspA domain deletion mutants of <i>S. pneumoniae</i>	98
6.2.4 IL-8 release by type II pneumocytes and nasopharyngeal cells in response to PspA domain mutants	99
6.3 Discussion	100

Chapter Seven: Investigation of the Specific Activities of Ply Responsible for Modulation of the Chemokine Response

7.1 Introduction	104
7.2 Results	105
7.2.1 Chemokine mRNA response elicited by A549 and Detroit-562 cells towards <i>S. pneumoniae</i> Ply point mutants	105
7.2.2 IL-8 secretion by A549 and Detroit-562 cells in response to D39 Ply point mutants	107
7.3 Discussion	108

Chapter Eight: Final Discussion

8.1 Future directions	119
------------------------------	------------

Bibliography	120
---------------------	------------

Abstract

Streptococcus pneumoniae (the pneumococcus) remains a major cause of morbidity and mortality worldwide, particularly in young children and the elderly. It is responsible for a spectrum of diseases ranging from otitis media, to potentially fatal conditions such as pneumonia and meningitis, and is estimated to cost health services billions of dollars each year. The interaction of *S. pneumoniae* with the host generally begins in the nasopharynx, and invasive disease is almost invariably preceded by nasopharyngeal colonisation. In some circumstances, *S. pneumoniae* may translocate from the nasopharynx to the lungs where pneumonia can develop, and inflammation is believed to play a role in this process. The presence of pneumococci in the lungs also triggers an inflammatory response, which is important for clearance of the bacteria. However, a prolonged inflammatory response leads to tissue damage, and is linked with a poor prognosis of disease. It has been shown that respiratory epithelial cells are able to play an active part in the response to respiratory pathogens by releasing chemokines that are responsible for neutrophil recruitment, and it has recently been shown that infection of type II pneumocytes with *S. pneumoniae* leads to the release of interleukin (IL)-8. In order to determine the role of specific pneumococcal factors in eliciting a CXC chemokine response from type II pneumocytes (A549) and nasopharyngeal cells (Detroit-562), monolayers of these cells were infected with wild type (WT) *S. pneumoniae* D39, or mutants deficient in choline binding protein A (CbpA), pneumococcal surface protein A (PspA), or pneumolysin (Ply), and the CXC chemokine mRNA response was measured by real-time RT-PCR. Release of IL-8 was also measured by ELISA. In response to WT D39, both A549 and Detroit-562 cells showed a significant increase in CXC chemokine mRNA, and IL-8 protein. This response was increased 2-fold when a CbpA-negative (Δ CbpA) mutant was used to infect cells, suggesting that CbpA may have an

inhibitory effect on the CXC chemokine response of these cells. Further investigation demonstrated that this activity is dependent on the N-terminal region of CbpA and that all three N-terminal domains are required for this effect, as deletion of any one of these domains had the same effect on the CXC chemokine response as removing CbpA altogether.

Infection with a PspA-negative mutant (Δ PspA) led to a 2-fold decrease in the CXC chemokine response of A549 cells, compared to infection with WT D39 at 2 h, but no difference was seen in the response of Detroit-562 cells to this mutant compared to WT D39. Thus, PspA appears to have the ability to stimulate an early CXC chemokine release from A549 cells. Deletion of the first of 2 regions of the N-terminal α -helical domain of PspA reduced the ability of *S. pneumoniae* to elicit a chemokine response to the same degree as removing PspA altogether, indicating that it is this region that is responsible for the chemokine inducing ability of PspA.

Ply appeared to have no effect on the CXC chemokine response of A549 cells with no obvious difference seen in the response of these cells to Δ Ply compared to WT D39. However, infection of Detroit-562 cells with Δ Ply led to a 2-fold decrease in IL-8 mRNA and protein release compared to WT D39. Using D39 strains producing mutant forms of Ply with reduced cytotoxicity and/or complement activating abilities, the role of the cytotoxic activity of Ply was demonstrated to be important in generation of a chemokine response from both cell lines. Infection of A549 or Detroit-562 cells with mutants producing Ply with only 0.02% or 0.1% haemolytic activity led to a 2-fold decrease in IL-8 release compared to that elicited by WT D39. The complement activating ability of Ply also appeared to be important in the generation of a CXC chemokine response from A549 cells. Cells infected with a mutant that produced Ply with no complement activating ability released significantly less IL-8 than cells infected with WT D39. This activity of Ply did not appear to have an effect on the CXC chemokine release of Detroit-562 cells. Thus all three virulence factors investigated had some role in the ability of *S. pneumoniae* to generate a CXC chemokine response from

respiratory epithelial cells, although their roles and the cell lines that were affected differed.